Patents by Inventor Liat Hayardeny
Liat Hayardeny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220362263Abstract: The present invention relates to unit dosage forms of 3D-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol™) and use thereof in the treatment and/or inhibition of fibrosis.Type: ApplicationFiled: July 13, 2022Publication date: November 17, 2022Applicant: GALMED RESEARCH AND DEVELOPMENT LTDInventors: LIAT HAYARDENY-NISSIMOV, Tali GORFINE, Allen BAHARAFF, Jose M. MATO DE LA PAZ
-
Patent number: 11197870Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.Type: GrantFiled: October 20, 2017Date of Patent: December 14, 2021Assignee: Galmed Research and Development LtdInventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
-
Publication number: 20210230213Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: ApplicationFiled: January 25, 2021Publication date: July 29, 2021Applicant: GALMED RESEARCH AND DEVELOPMENT LTD.Inventors: Allen Baharaff, Idit Eshkar-Oren, Liat Hayardeny-Nissimov
-
Publication number: 20200277326Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: ApplicationFiled: May 14, 2020Publication date: September 3, 2020Applicant: GALMED RESEARCH AND DEVELOPMENT LTDInventors: ALLEN BAHARAFF, Idit Eshkar-Oren, Liat Hayardeny-Nissimov
-
Publication number: 20190275061Abstract: The invention relates to inhibiting the development of hepatic fibrosis in a human subject afflicted with Non-Alcoholic Fatty Liver Disease and having a fibrosis score of zero comprising administering to the subject greater that 300 mg per day of 3?-arachidylamido-7?, 12?-dihydroxy-5?-cholan-24-oic acid (Aramchol), or a pharmaceutically acceptable salt thereof, thereby inhibiting the development of hepatic fibrosis in said subject.Type: ApplicationFiled: November 10, 2017Publication date: September 12, 2019Applicant: GALMED RESEARCH AND DEVELOPMENT LTDInventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato De La Paz
-
Publication number: 20190175619Abstract: The invention relates to the treatment, inhibition and reduction of fibrosis, including hepatic fibrosis. More specifically, the invention provides compositions and methods useful for the treatment and inhibition of fibrotic disorders, hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use, of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol™) or a pharmaceutically acceptable salt thereof in a split dose regimen of at least twice a day.Type: ApplicationFiled: November 7, 2018Publication date: June 13, 2019Applicant: GALMED RESEARCH AND DEVELOPMENT LTD.Inventors: Liat HAYARDENY-NISSIMOV, Tali GORFINE, Allen BAHARAFF, Jose M. MATO DE LA PAZ
-
Publication number: 20180125862Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.Type: ApplicationFiled: October 20, 2017Publication date: May 10, 2018Applicant: Galmed Research and Development Ltd.Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
-
Publication number: 20180064702Abstract: This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject. This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a progressive form of multiple sclerosis.Type: ApplicationFiled: November 13, 2017Publication date: March 8, 2018Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Dan Bar-Zohar, Liat Hayardeny, Yossi Gilgun Sherki, Tali Gorfine, Volker Knappertz, Ella Sorani
-
Publication number: 20180002753Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identifType: ApplicationFiled: January 19, 2017Publication date: January 4, 2018Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Amir TCHELET, Michael HAYDEN, Liat HAYARDENY, Colin James Douglas ROSS, Iris GROSSMAN, David LADKANI
-
Publication number: 20170354651Abstract: This invention provides a method of treating a subject afflicted with a neurodegenerative disease comprising periodic administration of an amount of laquinimod and an amount of fingolimod, wherein the amounts when taken together are effective to treat the subject. Also provided are packages and pharmaceutical compositions comprising laquinimod and fingolimod for treating a subject afflicted with a neurodegenerative disease. Also provided is a pharmaceutical composition comprising laquinimod for use as an add-on therapy or in combination with fingolimod, and a pharmaceutical composition comprising fingolimod for use as an add-on therapy or in combination with laquinimod, for treating said subject.Type: ApplicationFiled: August 4, 2017Publication date: December 14, 2017Applicant: Teva Pharmaceutical Industries Ltd.Inventors: Michael Hayden, Liat Hayardeny, David Ladkani
-
Publication number: 20170239234Abstract: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject.Type: ApplicationFiled: February 7, 2017Publication date: August 24, 2017Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Liat Hayardeny
-
Publication number: 20170224674Abstract: This invention provides a method of treating a subject afflicted with a neurodegenerative disease comprising periodic administration of an amount of laquinimod and an amount of fingolimod, wherein the amounts when taken together are effective to treat the subject. Also provided are packages and pharmaceutical compositions comprising laquinimod and fingolimod for treating a subject afflicted with a neurodegenerative disease. Also provided is a pharmaceutical composition comprising laquinimod for use as an add-on therapy or in combination with fingolimod, and a pharmaceutical composition comprising fingolimod for use as an add-on therapy or in combination with laquinimod, for treating said subject.Type: ApplicationFiled: April 21, 2017Publication date: August 10, 2017Applicant: Teva Pharmaceutical Industries Ltd.Inventors: Michael Hayden, Liat Hayardeny, David Ladkani
-
Patent number: 9702007Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identifType: GrantFiled: October 21, 2014Date of Patent: July 11, 2017Assignee: TEVA PHARMACEUTICALS INDUSTRIES, LTD.Inventors: Amir Tchelet, Michael Hayden, Liat Hayardeny, Colin James Douglas Ross, Iris Grossman, David Ladkani
-
Patent number: 9585878Abstract: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject.Type: GrantFiled: August 9, 2010Date of Patent: March 7, 2017Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Liat Hayardeny
-
Publication number: 20170003277Abstract: The present invention provides a process for characterizing a glatiramer acetate related drug substance or drug product comprising the steps of: a) obtaining a batch of the glatiramer acetate related drug substance or drug product; b) contacting mammalian cells with an amount of the glatiramer acetate related drug substance or drug product of step a); and c) i) determining the level of expression of at least one gene selected from the group consisting of ABCF2, ABI2, ACP6, AFG3L2, ALMS1, ARPC4, CALM3, CCDC64, CD84, CDC6, CHAF1A, CLU, COX11, DLGAP1, DTX4, FAM49B, FHL1, FNTB, GYPC, HFE, IL10, LPHN1, NACA, OLAH, PATZ1, PDK1, POLI, REEP5, RPL5, RPS6KA2, SEC31A, SETBP1, SNRPA1, SYNCRIP, TNFSF9, TOMM40, TPM1, TSHZ1, TSPAN13, UBAP2, VAV3, VDAC2, and ZFAND6; ii) determining the level of expression of at least one gene selected from the group consisting of BIRC3, CCL24, CCR1, CISH, CSF1R, CX3CR1, CXCL10, HSPD1, ICAM1, IL1B, IFNGR1, IL27, IL2RG, IL7R, IL1RN, MMP1, MMP9, MMP14, PGRMC1, PRDM1, CARD15, CCL2, CCL5, CD14,Type: ApplicationFiled: July 1, 2015Publication date: January 5, 2017Inventors: Michael Hayden, Fadi George Towfic, Sarah Elisabeth Kolitz, Benjamin James Zeskind, David Ladkani, Tal Hasson, Liat Hayardeny, Iris Grossman
-
Publication number: 20160243103Abstract: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum, level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject.Type: ApplicationFiled: February 22, 2016Publication date: August 25, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventor: Liat Hayardeny
-
Publication number: 20160201132Abstract: This invention provides a method of predicting clinical responsiveness to laquinimod therapy in a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising evaluating expression of a biomarker in the subject. This invention also provides a method of treating said subject comprising determining whether the subject is a laquinimod-responder by evaluating expression of a biomarker. Also provided is laquinimod or a pharmaceutical composition comprising laquinimod for use in treating said subject, and a therapeutic package for use in dispensing to said subject, wherein the subject has been identified as a laquinimod-responder or expression of a biomarker in the subject is up-regulated or suppressed.Type: ApplicationFiled: September 12, 2014Publication date: July 14, 2016Applicant: Teva Pharmaceutical Industries Ltd.Inventors: Liat Hayardeny, Anat Achiron, Michael Gurevich
-
Publication number: 20160074380Abstract: This invention provides a method of treating a subject afflicted with a neurodegenerative disease comprising periodic administration of an amount of laquinimod and an amount of fingolimod, wherein the amounts when taken together are effective to treat the subject. Also provided are packages and pharmaceutical compositions comprising laquinimod and fingolimod for treating a subject afflicted with a neurodegenerative disease. Also provided is a pharmaceutical composition comprising laquinimod for use as an add-on therapy or in combination with fingolimod, and a pharmaceutical composition comprising fingolimod for use as an add-on therapy or in combination with laquinimod, for treating said subject.Type: ApplicationFiled: September 15, 2015Publication date: March 17, 2016Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.Inventors: Michael Hayden, Liat Hayardeny, David Ladkani
-
Publication number: 20150110733Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identifType: ApplicationFiled: October 21, 2014Publication date: April 23, 2015Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Amir TCHELET, Michael HAYDEN, Liat HAYARDENY, Colin James Douglas ROSS, Iris GROSSMAN, David LADKANI
-
Publication number: 20140271532Abstract: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.Type: ApplicationFiled: May 30, 2014Publication date: September 18, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Rivka Kreitman, Liat Hayardeny, Eran Blaugrund, Ruth Levy